» Articles » PMID: 35330159

Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy Against Tumors

Overview
Journal Life (Basel)
Specialty Biology
Date 2022 Mar 25
PMID 35330159
Authors
Affiliations
Soon will be listed here.
Abstract

Immunotherapy has revolutionized the established therapeutics against tumors. As the major immunotherapy approach, immune checkpoint inhibitors (ICIs) achieved remarkable success in the treatment of malignancies. However, the clinical gains are far from universal and durable, because of the primary and secondary resistance of tumors to the therapy, or side effects induced by ICIs. There is an urgent need to find safe combinatorial strategies that enhance the response of ICIs for tumor treatment. Diets have an excellent safety profile and have been shown to play pleiotropic roles in tumor prevention, growth, invasion, and metastasis. Accumulating evidence suggests that dietary regimens bolster not only the tolerability but also the efficacy of tumor immunotherapy. In this review, we discussed the mechanisms by which tumor cells evade immune surveillance, focusing on describing the intrinsic and extrinsic mechanisms of resistance to ICIs. We also summarized the impacts of different diets and/or nutrients on the response to ICIs therapy. Combinatory treatments of ICIs therapy with optimized diet regimens own great potential to enhance the efficacy and durable response of ICIs against tumors, which should be routinely considered in clinical settings.

Citing Articles

Effects of dietary intervention on human diseases: molecular mechanisms and therapeutic potential.

Xiao Y, Gong Y, Qi Y, Shao Z, Jiang Y Signal Transduct Target Ther. 2024; 9(1):59.

PMID: 38462638 PMC: 10925609. DOI: 10.1038/s41392-024-01771-x.


Unraveling the Dietary Puzzle: Exploring the Influence of Diet, Nutraceuticals, and Supplements on Bladder Cancer Risk, Outcomes, and Immunotherapy Efficacy: Insights from the BLOSSOM Study and Beyond.

Buonerba C, Ingenito C, Di Trolio R, Cappuccio F, Rubino R, Piscosquito A Oncol Ther. 2024; 12(2):189-195.

PMID: 38416326 PMC: 11187017. DOI: 10.1007/s40487-024-00266-7.


Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer.

Marhold M, Udovica S, Halstead A, Hirdler M, Ferner M, Wimmer K Oncoimmunology. 2023; 12(1):2275846.

PMID: 38025838 PMC: 10653620. DOI: 10.1080/2162402X.2023.2275846.


What We Have Learned About Combining a Ketogenic Diet and Chemoimmunotherapy: a Case Report and Review of Literature.

Sims D, Liman A, Leung V, Hwang A, Means J, Liman A Fed Pract. 2023; 40(Suppl 3):S98-S104.

PMID: 38021096 PMC: 10681018. DOI: 10.12788/fp.0399.


The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer.

Duttagupta S, Hakozaki T, Routy B, Messaoudene M Curr Oncol. 2023; 30(11):9406-9427.

PMID: 37999101 PMC: 10669980. DOI: 10.3390/curroncol30110681.


References
1.
Rom-Jurek E, Kirchhammer N, Ugocsai P, Ortmann O, Wege A, Brockhoff G . Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice. Int J Mol Sci. 2018; 19(2). PMC: 5855785. DOI: 10.3390/ijms19020563. View

2.
Gudas L, Wagner J . Retinoids regulate stem cell differentiation. J Cell Physiol. 2010; 226(2):322-30. PMC: 3315372. DOI: 10.1002/jcp.22417. View

3.
Bober P, Alexovic M, Talian I, Tomkova Z, Viscorova Z, Benckova M . Proteomic analysis of the vitamin C effect on the doxorubicin cytotoxicity in the MCF-7 breast cancer cell line. J Cancer Res Clin Oncol. 2016; 143(1):35-42. DOI: 10.1007/s00432-016-2259-4. View

4.
Chocarro de Erauso L, Zuazo M, Arasanz H, Bocanegra A, Hernandez C, Fernandez G . Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?. Front Pharmacol. 2020; 11:441. PMC: 7154133. DOI: 10.3389/fphar.2020.00441. View

5.
Fine E, Feinman R . Insulin, carbohydrate restriction, metabolic syndrome and cancer. Expert Rev Endocrinol Metab. 2018; 10(1):15-24. DOI: 10.1586/17446651.2014.960392. View